Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NetraMark Holdings ( (TSE:AIAI) ) just unveiled an announcement.
NetraMark Holdings Inc. announced that it will present new data on its AI-based clinical trial treatment separation tools at the ISCTM Annual Meeting. The tools are designed to improve predictive modeling and patient stratification in CNS clinical trials, offering significant advancements in identifying effective treatments for disorders like major depressive disorder and schizophrenia. These innovative methods have shown improved accuracy and specificity over traditional models, potentially transforming the design and analysis of such trials.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in generative AI software focused on clinical trial analytics. The company specializes in developing machine learning tools that enhance predictive modeling and patient stratification, particularly in psychiatric clinical trials.
YTD Price Performance: 7.43%
Average Trading Volume: 8,232
Technical Sentiment Consensus Rating: Sell
See more insights into AIAI stock on TipRanks’ Stock Analysis page.